[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2861229T - Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal - Google Patents

Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal

Info

Publication number
PT2861229T
PT2861229T PT137287587T PT13728758T PT2861229T PT 2861229 T PT2861229 T PT 2861229T PT 137287587 T PT137287587 T PT 137287587T PT 13728758 T PT13728758 T PT 13728758T PT 2861229 T PT2861229 T PT 2861229T
Authority
PT
Portugal
Prior art keywords
nicotinamide
tryptophan
pharmaceutical composition
composition containing
nicotinic acid
Prior art date
Application number
PT137287587T
Other languages
English (en)
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Publication of PT2861229T publication Critical patent/PT2861229T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT137287587T 2012-06-15 2013-06-14 Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal PT2861229T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15

Publications (1)

Publication Number Publication Date
PT2861229T true PT2861229T (pt) 2021-01-05

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137287587T PT2861229T (pt) 2012-06-15 2013-06-14 Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal

Country Status (32)

Country Link
US (2) US10426765B2 (pt)
EP (2) EP3831379A1 (pt)
JP (3) JP6855165B2 (pt)
KR (2) KR102211832B1 (pt)
CN (2) CN104363907A (pt)
AR (1) AR091465A1 (pt)
AU (1) AU2013276451B2 (pt)
BR (1) BR112014030835B1 (pt)
CA (1) CA2876540C (pt)
CY (1) CY1123999T1 (pt)
DK (1) DK2861229T3 (pt)
ES (1) ES2859758T3 (pt)
HK (1) HK1204972A1 (pt)
HR (1) HRP20210090T1 (pt)
HU (1) HUE053359T2 (pt)
IL (1) IL236205B (pt)
IN (1) IN2014DN10260A (pt)
JO (1) JO3578B1 (pt)
LT (1) LT2861229T (pt)
MX (1) MX370795B (pt)
NZ (1) NZ702297A (pt)
PH (1) PH12014502744A1 (pt)
PL (1) PL2861229T3 (pt)
PT (1) PT2861229T (pt)
RS (1) RS61288B1 (pt)
RU (1) RU2657797C2 (pt)
SA (1) SA113340643B1 (pt)
SG (1) SG11201408251SA (pt)
SI (1) SI2861229T1 (pt)
TW (1) TWI624260B (pt)
WO (1) WO2013186355A1 (pt)
ZA (1) ZA201408922B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2861229T (pt) 2012-06-15 2021-01-05 Conaris Res Institute Ag Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal
JP6473938B2 (ja) 2013-06-05 2019-02-27 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 抗線維化化合物、その方法および使用
US10456389B2 (en) 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
ES2788866T3 (es) * 2013-12-13 2020-10-23 Conaris Res Institute Ag Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida para su uso en influir beneficiosamente en los niveles de lípidos en sangre mediante la modificación de la microbiota intestinal
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
KR20160088436A (ko) 2013-12-13 2016-07-25 코나리스 리써치 인스티튜트 아게 니코틴아미드 및 5-아미노살리실산의 조합을 포함하는, 장내 세균총에 유익한 영향을 미치거나 및/또는 위장 염증을 치료하기 위한 약학 조성물
WO2015124637A1 (en) * 2014-02-18 2015-08-27 Conaris Research Institute Ag Methods and compositions for intestinal microenvironment transfer
CN106413680A (zh) * 2014-05-12 2017-02-15 荷兰联合利华有限公司 用于诱导抗微生物肽生成的烟酰胺
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
AU2017248818B2 (en) * 2016-04-14 2023-01-12 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
KR20180135020A (ko) * 2016-04-19 2018-12-19 훼링 비.브이. 니코틴아미드의 경구 약제학적 조성물
US10874617B2 (en) 2016-04-19 2020-12-29 Ferring B.V. Oral pharmaceutical compositions of mesalazine
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
EP3925450A4 (en) * 2019-02-12 2022-09-21 Megumi Tanaka FOOD OR DRINK FOR BABIES AND INFANTS, METHOD FOR IMPROVING THE INTESTINAL ENVIRONMENT OF A BABY OR INFANT, AND METHOD FOR BOOSTING THE IMMUNITY OF THE BABY OR INFANT
US20220175724A1 (en) * 2019-03-28 2022-06-09 Tohoku University Prophylactic or Therapeutic Agent for Cancer
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
JP2023550994A (ja) * 2020-11-27 2023-12-06 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物
JPWO2023002939A1 (pt) * 2021-07-19 2023-01-26
WO2023187003A1 (en) * 2022-03-30 2023-10-05 Conaris Research Institute Ag Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases
KR20240123060A (ko) 2023-02-06 2024-08-13 한림대학교 산학협력단 아토피 피부염 진단용 바이오마커

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
EA005030B1 (ru) * 1998-12-23 2004-10-28 Джи.Ди.Сирл Ллс Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных никотиновой кислоты, фармкомпозиция и способ профилактики и лечения гиперлипидемических состояний
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
AU2001278699A1 (en) 2000-08-08 2002-02-18 Shionogi And Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
EP1751096A4 (en) 2004-05-27 2009-01-07 Antibe Therapeutics Inc 4- OR 5- AMINOSALICYLIC ACID SALT
PL1811979T3 (pl) * 2004-09-27 2009-04-30 Sigmoid Pharma Ltd Mikrokapsułki zawierające metyloksantynę i kortykosteroid
EP1920770A4 (en) 2005-07-01 2010-09-29 Ajinomoto Kk THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE
WO2007103540A2 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
ITMI20061932A1 (it) * 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
US20090104171A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
US20110104282A1 (en) * 2008-04-25 2011-05-05 Karolinska Institutet Innovations Ab New Therapy of Treatment of the Irritable Bowel Syndrome
CN102083466A (zh) * 2008-05-20 2011-06-01 科莱尼斯医疗公司 用于组合疗法的烟酸和nsaid
AU2009256394A1 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
US8865688B2 (en) 2008-10-03 2014-10-21 Dr. Falk Pharma Gmbh Compositions and methods for treatment of bowel diseases with granulated mesalamine
JP2011121889A (ja) * 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) * 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
PT2861229T (pt) 2012-06-15 2021-01-05 Conaris Res Institute Ag Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal
US10456389B2 (en) 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
KR20180135020A (ko) 2016-04-19 2018-12-19 훼링 비.브이. 니코틴아미드의 경구 약제학적 조성물

Also Published As

Publication number Publication date
AU2013276451B2 (en) 2018-03-29
AU2013276451A1 (en) 2015-01-15
AR091465A1 (es) 2015-02-04
KR102211832B1 (ko) 2021-02-02
ES2859758T3 (es) 2021-10-04
RS61288B1 (sr) 2021-02-26
MX370795B (es) 2020-01-08
US10426765B2 (en) 2019-10-01
CY1123999T1 (el) 2022-05-27
IN2014DN10260A (pt) 2015-08-07
SI2861229T1 (sl) 2021-03-31
DK2861229T3 (da) 2021-01-18
CA2876540C (en) 2022-11-29
LT2861229T (lt) 2021-01-25
CN104363907A (zh) 2015-02-18
US20150126462A1 (en) 2015-05-07
CA2876540A1 (en) 2013-12-19
EP2861229A1 (en) 2015-04-22
JO3578B1 (ar) 2020-07-05
TW201400116A (zh) 2014-01-01
SA113340643B1 (ar) 2019-10-06
PH12014502744A1 (en) 2015-02-02
NZ702297A (en) 2016-11-25
US20200009124A1 (en) 2020-01-09
KR20200011619A (ko) 2020-02-03
CN108273064A (zh) 2018-07-13
EP2861229B1 (en) 2020-12-23
BR112014030835B1 (pt) 2022-01-11
KR20150021071A (ko) 2015-02-27
HK1204972A1 (en) 2015-12-11
RU2014148239A (ru) 2016-08-10
IL236205B (en) 2020-02-27
ZA201408922B (en) 2016-10-26
JP2022017332A (ja) 2022-01-25
TWI624260B (zh) 2018-05-21
MX2014015217A (es) 2015-03-05
JP2015519388A (ja) 2015-07-09
PL2861229T3 (pl) 2021-08-09
HUE053359T2 (hu) 2021-06-28
SG11201408251SA (en) 2015-01-29
WO2013186355A1 (en) 2013-12-19
RU2657797C2 (ru) 2018-06-15
BR112014030835A2 (pt) 2017-06-27
JP2019069972A (ja) 2019-05-09
EP3831379A1 (en) 2021-06-09
JP6855165B2 (ja) 2021-04-07
IL236205A0 (en) 2015-01-29
HRP20210090T1 (hr) 2021-03-05

Similar Documents

Publication Publication Date Title
HK1204972A1 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota //
IL230786A0 (en) Heterocyclic derivatives and pharmaceutical drugs
PT3079675T (pt) Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal
IL238060B (en) 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them
IL256646B (en) History of azaquinazoline carboxamides and pharmaceutical preparations containing them
EP2668186A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
IL235947A0 (en) History of isonicotinamide in solid state and pharmaceutical preparations containing them
HK1187336A1 (en) Pharmaceutical composition comprising pyridone derivatives
RS57107B1 (sr) Derivat piridona i medikamenti koji isti sadrže
ZA201501095B (en) Pyridine derivative and medicine
PL399613A1 (pl) Pochodne estrów diarylowych kwasów 1-aminoalkanofosfonowych, sposób wytwarzania pochodnych estrów diarylowych kwasów 1-aminoalkanofosfonowych oraz ich zastosowanie
HK1203955A1 (zh) 反式- -癸烯酸衍生物及含有其的藥物
IL234614B (en) Pharmaceutical composition and preparation method thereof
EP2930175A4 (en) NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF
TH1401007439A (th) องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้